Edison Oncology Holding Corp
EOHCDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
PTC-589
Parkinson's Disease
EPI-743
Noise-induced Hearing Loss
EPI-743 400mg
Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PTC-589 | Phase 2 | Parkinson's Disease | - | - |
EPI-743 | Phase 2 | Noise-induced Hearing Loss | - | - |
EPI-743 400mg | Phase 2 | Parkinson's Disease | - | - |
Frequently asked questions
What is in Edison Oncology Holding Corp's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Edison Oncology Holding Corp's (EOHC) pipeline across Phase 2. Its lead program is PTC-589 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Edison Oncology Holding Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Edison Oncology Holding Corp (EOHC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EOHC biotech catalysts?→
Add EOHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Edison Oncology Holding Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.